方法与患者因素对精神病性障碍血清NMDAR IgG抗体检测影响的荟萃分析
检测方法(活细胞法vs固定细胞法)、疾病阶段和研究质量显著影响异质性,活细胞法阳性率和OR更高。
要点
- 活细胞法检测NMDAR IgG抗体阳性率及OR显著高于固定细胞法。
- 横断面研究中首发患者阳性率高于多发作或混合样本。
- 病例对照研究中低质量研究报告的OR更高。
核心结论
- 使用活细胞法检测时NMDAR IgG抗体在精神病性障碍患者中更常见,且阳性率估计值更高。
- 疾病阶段和研究质量对异质性的影响在不同研究设计间不一致。
研究设计与样本
- 系统检索Web of Science和Ovid(MEDLINE和PsycINFO)2000年1月1日至2019年5月5日的横断面和病例对照研究。
- 纳入28项研究,包括14项横断面研究和14项病例对照研究。
- 采用随机效应模型合并比例和比值比(OR),并用单变量随机效应荟萃回归分析研究因素对异质性的影响。
关键数值与推荐
- 异质性显著与检测方法类型(横断面和病例对照研究均相关)、疾病阶段(横断面研究)和研究质量(病例对照研究)相关。
临床怎么用
- 临床解读NMDAR IgG抗体检测结果时需考虑检测方法,活细胞法可能提高阳性检出率。
- 对首发精神病患者应关注NMDAR IgG抗体检测,其阳性率可能更高。
- 研究质量影响病例对照研究的结果,临床应优先参考高质量研究证据。
局限性
- 研究间异质性较高(横断面研究I2 56%),可能影响合并结果的可靠性。
- 疾病阶段和研究质量对异质性的影响在不同研究设计间不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibodies targeting the N-methyl-D-aspartate receptor (NMDAR) have been detected in patients with psychosis. However, studies measuring the IgG subclass in serum have provided variable estimates of prevalence, and it is unclear whether these antibodies are more common in patients than controls. Because these inconsistencies could be due to methodological approaches and patient characteristics, we aimed to investigate the effect of these factors on heterogeneity. METHODS: We searched Web of Science and Ovid (MEDLINE and PsycINFO) for cross-sectional and case-control studies published between Jan 1, 2000, and May 5, 2019, that reported NMDAR IgG antibody seropositivity in patients with psychosis. Pooled proportions and odds ratios (ORs) were derived using random-effects models. We estimated between-study variance (τ2) and the proportion of observed variance due to heterogeneity (I2). We then used univariable random-effects meta-regression analysis to investigate the effect of study factors on heterogeneity of proportions and ORs. Our protocol was registered on PROSPERO (CRD42018099874). FINDINGS: Of 1276 articles in the initial search, 28 studies were eligible for inclusion, including 14 cross-sectional studies and 14 case-control studies. In cross-sectional studies, NMDAR IgG antibodies were detected in 0·73% (95% CI 0·09-1·38; I2 56%; p=0·026) of patients with psychosis, and in case-control studies, patients with psychosis were not significantly more likely to be seropositive than healthy individuals (OR 1·57, 95% CI 0·78-3·16; I2 15%; p=0·20). Meta-regression analyses indicated that heterogeneity was significantly associated with assay type across both study designs, illness stage in cross-sectional studies, and study quality in case-control studies. Compared with studies using a fixed cell-based assay, cross-sectional and case-control studies using the live method yielded higher pooled prevalence estimates (0·36% [95% CI -0·23 to 0·95] vs 2·97% [0·70 to 5·25]) and higher ORs (0·65 [0·33 to 1·29] vs 4·43 [1·73 to 11·36]). In cross-sectional studies, the prevalence was higher in exclusively first-episode samples than in multi-episode or mixed samples (2·18% [0·25 to 4·12] vs 0·16% [-0·31 to 0·63]), and in case-control studies, higher ORs were reported in low-quality studies than in high-quality studies (3·80 [1·47 to 9·83] vs 0·72 [0·36 to 1·42]). INTERPRETATION: Higher estimates of NMDAR IgG antibody prevalence have been obtained with the live cell-based assay, and studies using this method find that seropositivity is more common in patients with psychosis than in controls. The effects of illness stage and study quality on heterogeneity were not consistent across study designs, and we provide clear recommendations for clinicians and researchers regarding interpreting these findings. FUNDING: None.
引用
- Cullen AE, Palmer-Cooper EC, Hardwick M, et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case-control studies. Lancet Psychiatry. 2020. PMID: 33357497. doi:10.1016/S2215-0366(20)30432-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。